Pharmaceutical companies face a major challenge that threatens reimbursement and value capture: The potential disruption from real world evidence (RWE) as a factor in evaluating new drugs. The emergence of health technology assessment practices today makes it still more difficult to achieve attractive reimbursement value for newly launched products.
Strategy& senior partner Viren Doshi discusses the challenges facing oil and gas players in the current landscape of geopolitical uncertainty where there is less clarity around pricing and where supply exceeds demand. Looking ahead what should oil and gas companies expect.
Is your company lined up the right way to tackle the intense challenges that business faces today? Our Fit for Growth* approach is a proven model for unlocking performance that helps companies manage their cost in a more strategic way and thereby allows them to cut costs and grow stronger at the same time.
Looking to give your company a digital edge? Focus on the top three digital trends shaping the future – mobile, personalization, and data analytics. Watch Chris Vollmer, Managing Director of Strategy&’s Digital Services, explain his key insights on how to get ahead in the digital race.
|Page 1 2 3 4 5 6 7 8 9 10 … All||Next >|